all about terminal illnesses
← All diseases Brain and nervous system

Spinal muscular atrophy (SMA)

Would you like to receive a message when there is new research about Spinal Muscular Atrophy (SMA)? This is possible with an account. Create a free account or log in.

Last updated: 2026-08-10 · automatically checked, spot-checked

# Treatment options for spinal muscular atrophy

The treatment of spinal muscular atrophy (SMA) aims to slow muscle deterioration, preserve function, and improve quality of life. In recent years, several medicines have been approved that directly address the genetic cause. Additionally, supportive care remains essential: physiotherapy, speech therapy, nutritional support, and assistance with breathing problems.

Which treatment is suitable depends on the type of SMA, the patient's age, and how advanced the muscle deterioration already is. Early diagnosis and prompt initiation of treatment significantly improve the chance of preserving function.

---

Gene therapy

ProveniIncluded in official guidelines, or approved by EMA or FDA

In gene therapy, a working copy of the missing SMN gene is delivered directly into the body via a virus. This helps cells produce the SMN protein again. The treatment is administered once via injection into the spinal canal or via intravenous infusion.

This approach works best when given early in the disease process — especially in young children and in pre-symptomatic patients (born with the gene defect but without symptoms yet). In cases of already advanced muscle deterioration, damaged nerves cannot be restored.

Known side effects include reactions to the viral carrier material (which activates the immune system) and, in rare cases, liver inflammation. These are usually identified and treated in a hospital setting.

---

Splicing modifiers (antisense oligonucleotides and risdiplam)

ProveniIncluded in official guidelines, or approved by EMA or FDA

These drugs work at the moment of DNA reading in cells. They encourage the body to produce sufficient SMN protein from the underlying SMN2 gene, which is almost identical to the defective SMN1 gene.

**Antisense oligonucleotides** (such as nusinersen) are administered regularly via injection into the spinal canal. **Risdiplam** is a tablet or liquid taken by mouth.

Both types are included in official treatment guidelines. Studies show that they can slow muscle deterioration and in some cases even cautiously improve function, especially when given early in the disease.

Side effects of splicing modifiers can include headaches, back pain, tremors, and, rarely, severe reactions. Risdiplam can also cause sleep problems. These drugs are administered and monitored under medical supervision.

---

Supportive care and physiotherapy

ProveniIncluded in official guidelines, or approved by EMA or FDA

Regardless of which medicine is used, physical therapy remains important. Physiotherapy helps keep muscles as active and flexible as possible. Speech therapists work on chewing and swallowing, especially in types where facial and throat muscles also weaken.

When breathing becomes more difficult, a sleep apnea device (CPAP) can keep oxygen and CO₂ levels balanced at night. In severe cases, mechanical ventilation may be necessary.

Nutritional support — sometimes via a feeding tube through the nose or directly into the stomach — ensures that patients receive sufficient calories and fluid intake when eating and drinking become difficult.

Bone weakening (osteoporosis) is a common side effect and can be prevented with adequate calcium and vitamin D intake and, where necessary, additional medication.

These measures are not 'optional'; they significantly improve comfort and life expectancy.

---

Treatment of stooped posture (camptocormia)

When the back muscles weaken severely, the spine can bend forward (camptocormia). This can severely limit breathing, food intake, and quality of life.

**Botulinum toxin treatments**

ResearchediPositive results in clinical studies, not yet standard treatment

Botulinum toxin is injected locally into specific back muscles to relax them. This can partially correct the forward bending and give patients a more upright posture. The effect is temporary and repetition is needed.

This is not yet standard recommended in all guidelines, but recent reviews show cautious benefits, especially for targeted body areas. Side effects are usually local and minor.

**Back support and orthoses**

ProveniIncluded in official guidelines, or approved by EMA or FDA

Special support corsets can support the spine and reduce pain. These are non-pharmacological and have no side effects, although they require adjustments and regular checks for pressure points.

---

Experimental approaches

ExperimentaliOngoing in study setting, outcome still unknown

A number of medicines are currently being investigated:

- **Salanersen** (and other newer generation antisense oligonucleotides) are being tested in clinical trials in pre-symptomatic children — that is, before symptoms occur. Early results suggest that preventive treatment may be even more effective.

- **Combination therapy** — the simultaneous use of gene therapy and splicing agents — is being investigated in studies to see if this works better than either drug alone.

- **Investigations into glymphatic dysfunction** (problems with waste removal in nerve tissue in SMA types 2 and 3) may lead to additional mechanisms to prevent nerve cell damage.

These treatments are not yet available outside research settings.

---

Treatment of additional symptoms

**Sleep apnea**

ProveniIncluded in official guidelines, or approved by EMA or FDA

Many patients with SMA develop sleep apnea (breathing pauses during sleep). This is diagnosed with sleep studies and treated with nighttime ventilation (CPAP or bilevel PAP). This significantly improves oxygen levels and sleep quality.

Recent studies are investigating how new medicines (particularly risdiplam) affect the sleep apnea pattern — sometimes improving it, sometimes leaving it unchanged.

**Autonomic dysfunction**

ResearchediPositive results in clinical studies, not yet standard treatment

Some patients with SMA have problems with heart rhythm, blood pressure and sweating. This is increasingly recognized as part of the disease. Medicines that regulate the autonomic nervous system are the subject of research.

**Pain and spasticity**

ProveniIncluded in official guidelines, or approved by EMA or FDA

Muscle cramps and pain are common. These can be helped with physiotherapy, sometimes combined with muscle relaxants. Botulinum toxin is also used for more generalized spasticity when it is severe.

---

Provider supportive care

Regardless of which medicine is used, coordination between neurologists, rehabilitation physicians, pulmonologists and other specialists remains important. In many countries, SMA centers work with this multidisciplinary model. This helps identify complications early and tailor treatment to what works for that specific patient.

Psychological support for patients and families is also part of good care, given the impact of a progressive muscle disease on daily life and future plans.

---

_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._

↑ Back to top

Sources used

Above each source is one sentence describing what the research is about, so you don't have to rely on an English technical title. More studies on Spinal Muscular Atrophy (SMA) can be found at publications and studies.

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.